Tuesday, March 8, 2022 Daily Archives

Material Transformation in Wet Granulation – The Effect of Continuous Process Dynamics, Material and Formulation Properties

Continuous manufacturing (CM) is increasingly used as an alternative to traditional batch manufacturing of solid pharmaceutical dosage forms. Wet granulation is one of the manufacturing technologies that was successfully migrated from batch to continuous processing. Thereby, the residence time of material under (stress) conditions is significantly reduced which in many cases is a main advantage of CM. However, in other cases with slow transformation processes this raises new challenges. In particular, the question arises as to which process parameters and…

IDT Biologika and Exothera team on viral vaccine manufacturing

The partnership will see IDT Biologika and Exothera collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. According to both contract development manufacturing organizations (CDMOs), the study will focus on Modified Vaccinia Ankara (MVA) as a first example for IDT’s wide range of vector technologies. “The MVA is a viral vector that has been successfully validated with a long history of use in clinical trials. MVA expressing recombinant antigens is a flexible vaccine tool that has been shown…

The 4 degrees of automation in cell therapy manufacture

With cell therapy firms looking beyond manual production methods, Cellares claims its ‘factory-in-a-box’ Cell Shuttle platform can offer the ultimate in walk-away automation on an industrial-scale. For years, industry has looked to automated processes to make cell therapies safely and at scale. Success has been variable, but developers continue investing in automated technologies to help make their complex therapies cost-effective. “A lot of people agree that automation is the way to go,†Fabian Gerlinghaus, co-founder and CEO of Cellares told…

Moderna picks Kenya for mRNA facility

Moderna has entered into a Memorandum of Understanding (MoU) with the Government of the Republic of Kenya to establish Kenya as the location for its mRNA plant. Moderna announced the $500 million investment in October 2021 but did not disclose where the messenger RNA (mRNA) manufacturing facility would be built. Now, with the assistance of the US Government, the firm has entered into a MoU to confirm that the facility will be located in Kenya. The aim of the facility…